{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T18:41:53Z","timestamp":1769366513070,"version":"3.49.0"},"reference-count":37,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the RUDN University Strategic Academic Leadership Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This work aimed to develop and characterize a water-soluble, high-release active pharmaceutical ingredient (API) composite based on the practically water-insoluble API N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide (GML-3), a substance with antidepressant and anxiolytic action. This allows to ensure the bioavailability of the medicinal product of combined action. Composites obtained by the method of creating amorphous solid dispersions, where polyvinylpyrrolidone (PVP) or Soluplus\u00ae was used as a polymer, were studied for crystallinity, stability and the release of API from the composite into purified water. The resulting differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), and dissolution test data indicate that the resulting composites are amorphous at 1:15 API: polymer ratios for PVP and 1:5 for Soluplus\u00ae, which ensures the solubility of GML-3 in purified water and maintaining the supercritical state in solution.<\/jats:p>","DOI":"10.3390\/ijms241512215","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T01:28:46Z","timestamp":1690766926000},"page":"12215","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Composites of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide with Polymers: Effect of Crystallinity on Solubility and Stability"],"prefix":"10.3390","volume":"24","author":[{"given":"Vladimir B.","family":"Markeev","sequence":"first","affiliation":[{"name":"V.V. Zakusov Research Institute of Pharmacology, 8 Baltiyskaya St., 125315 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenia V.","family":"Blynskaya","sequence":"additional","affiliation":[{"name":"V.V. Zakusov Research Institute of Pharmacology, 8 Baltiyskaya St., 125315 Moscow, Russia"},{"name":"Institute of Biochemical Technology and Nanotechnology, Peoples\u2019 Friendship University of Russia n.a. P. Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8321-6952","authenticated-orcid":false,"given":"Sergey V.","family":"Tishkov","sequence":"additional","affiliation":[{"name":"V.V. Zakusov Research Institute of Pharmacology, 8 Baltiyskaya St., 125315 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin V.","family":"Alekseev","sequence":"additional","affiliation":[{"name":"V.V. Zakusov Research Institute of Pharmacology, 8 Baltiyskaya St., 125315 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna I.","family":"Marakhova","sequence":"additional","affiliation":[{"name":"Institute of Biochemical Technology and Nanotechnology, Peoples\u2019 Friendship University of Russia n.a. P. Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-8571","authenticated-orcid":false,"given":"Alexandre A.","family":"Vetcher","sequence":"additional","affiliation":[{"name":"Institute of Biochemical Technology and Nanotechnology, Peoples\u2019 Friendship University of Russia n.a. P. Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia"},{"name":"Complementary and Integrative Health Clinic of Dr. Shishonin, 5, Yasnogorskaya St., 117588 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Y.","family":"Shishonin","sequence":"additional","affiliation":[{"name":"Complementary and Integrative Health Clinic of Dr. Shishonin, 5, Yasnogorskaya St., 117588 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1016\/j.bmc.2015.04.049","article-title":"Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo[1,2-a]pyrazine-3-carboxamides","volume":"23","author":"Mokrov","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_2","first-page":"7","article-title":"Pharmacological study of new compounds acting as regulators of 18-kDa translocator protein ligands","volume":"79","author":"Yarkov","year":"2016","journal-title":"Eksp. Klin. Farmakol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11094-016-1476-0","article-title":"Anxiolytic activity of original pyrrolo[1,2-a]pyrazine derivatives (TSPO ligands) depends on neurosteroid biosynthesis","volume":"50","author":"Yarkova","year":"2016","journal-title":"Pharm. Chem. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2017.11.005","article-title":"Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs","volume":"269","author":"Davis","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"120301","DOI":"10.1016\/j.lfs.2022.120301","article-title":"Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs","volume":"291","author":"Khan","year":"2022","journal-title":"Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"119741","DOI":"10.1016\/j.ijpharm.2020.119741","article-title":"Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs","volume":"588","author":"Bazzo","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpha.2018.09.003","article-title":"Silymarin-laden PVP-PEG polymeric composite for enhanced aqueous solubility and dissolution rate: Preparation and in vitro characterization","volume":"9","author":"Yousaf","year":"2019","journal-title":"J. Pharm. Anal."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"119240","DOI":"10.1016\/j.ijpharm.2020.119240","article-title":"Effect of the third component on the aging and crystallization of cinnarizine-soluplus\u00ae binary solid dispersion","volume":"580","author":"Tian","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jsps.2016.09.013","article-title":"Investigation of the in vitro performance difference of drug-Soluplus\u00ae and drug-PEG 6000 dispersions when prepared using spray drying or lyophilization","volume":"25","author":"Altamimi","year":"2017","journal-title":"Saudi Pharm. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103980","DOI":"10.1016\/j.jddst.2022.103980","article-title":"Polymeric solid dispersion Vs co-amorphous technology: A critical comparison","volume":"78","author":"Vullendula","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105642","DOI":"10.1016\/j.ejps.2020.105642","article-title":"Evaluation of rivaroxaban amorphous solid dispersions physical stability via molecular mobility studies and molecular simulations","volume":"157","author":"Kapourani","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"122564","DOI":"10.1016\/j.ijpharm.2022.122564","article-title":"Stability and intrinsic dissolution of vacuum compression molded amorphous solid dispersions of efavirenz","volume":"632","author":"Jorgensen","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijpharm.2019.03.039","article-title":"Kinetic stability of amorphous solid dispersions with high content of the drug: A fast scanning calorimetry investigation","volume":"562","author":"Lapuk","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"120902","DOI":"10.1016\/j.ijpharm.2021.120902","article-title":"Production and stability of amorphous solid dispersions produced by a Freeze-drying method from DMSO","volume":"606","author":"Valkama","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_15","first-page":"1495","article-title":"A Mechanistic Model for Predicting the Physical Stability of Amorphous Solid Dispersions","volume":"110","author":"Ojo","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.xphs.2022.08.007","article-title":"Considerations in the Development of Physically Stable High Drug Load API-Polymer Amorphous Solid Dispersions in the Glassy State","volume":"112","author":"Newman","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105276","DOI":"10.1016\/j.ejps.2020.105276","article-title":"Amorphous solid dispersions containing residual crystallinity: Influence of seed properties and polymer adsorption on dissolution performance","volume":"146","author":"Moseson","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"122745","DOI":"10.1016\/j.ijpharm.2023.122745","article-title":"Moisture sorption by polymeric excipients commonly used in amorphous solid dispersions and its effect on glass transition temperature: III. Methacrylic acid-methyl methacrylate and related copolymers (Eudragit\u00ae)","volume":"636","author":"Patel","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119845","DOI":"10.1016\/j.ijpharm.2020.119845","article-title":"Physical stability of hydroxypropyl methylcellulose-based amorphous solid dispersions: Experimental and computational study","volume":"589","author":"Iemtsev","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejpb.2017.12.002","article-title":"Physical stability of API\/polymer-blend amorphous solid dispersions","volume":"124","author":"Lehmkemper","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106086","DOI":"10.1016\/j.ejps.2021.106086","article-title":"Role of polymers in the physical and chemical stability of amorphous solid dispersion: A case study of carbamazepine","volume":"169","author":"Yu","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119925","DOI":"10.1016\/j.ijpharm.2020.119925","article-title":"Physical stability of amorphous pharmaceutical solids: Nucleation, crystal growth, phase separation and effects of the polymers","volume":"590","author":"Shi","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jsps.2022.04.002","article-title":"Solubility enhancement of some poorly soluble drugs by solid dispersion using Ziziphus spina-christi gum polymer","volume":"30","author":"Alwossabi","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejpb.2020.11.025","article-title":"Combining crystalline and polymeric excipients in API solid dispersions\u2014Opportunity or risk?","volume":"158","author":"Veith","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101182","DOI":"10.1016\/j.jddst.2019.101182","article-title":"Multi-scale analysis of amorphous solid dispersions prepared by freeze-drying of ibuprofen loaded acrylic polymer nanoparticles","volume":"53","author":"Hassouna","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"121625","DOI":"10.1016\/j.ijpharm.2022.121625","article-title":"Effects of polymer addition on the non-strongly interacting binary co-amorphous system carvedilol-tryptophan","volume":"617","author":"Wang","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102278","DOI":"10.1016\/j.jddst.2020.102278","article-title":"Effects of polymer molecular weight on curcumin amorphous solid dispersion; at-line monitoring system based on attenuated total reflectance mid-infrared and near-infrared spectroscopy","volume":"61","author":"Mai","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.xphs.2022.04.002","article-title":"Adding a New Dimension to the Amorphous Solid Dispersion Phase Diagram: Studying Dissolution Kinetics of Crystalline Drugs in a Polymer Matrix Using Temperature Dependent XRPD and DSC","volume":"111","author":"Seiler","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.xphs.2022.07.020","article-title":"Moisture Sorption by Polymeric Excipients Commonly Used in Amorphous Solid Dispersions and its Effect on Glass Transition Temperature: II. Cellulosic Polymers","volume":"111","author":"Patel","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.xphs.2021.01.036","article-title":"Application of Thermodynamic Phase Diagrams and Gibbs Free Energy of Mixing for Screening of Polymers for Their Use in Amorphous Solid Dispersion Formulation of a Non-Glass-Forming Drug","volume":"110","author":"Mamidi","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s11095-017-2174-7","article-title":"The Need for Restructuring the Disordered Science of Amorphous Drug Formulations","volume":"34","author":"Edueng","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejpb.2019.10.010","article-title":"Rivaroxaban polymeric amorphous solid dispersions: Moisture-induced thermodynamic phase behavior and intermolecular interactions","volume":"145","author":"Kapourani","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.xphs.2020.12.007","article-title":"Correlation ship of Drug-Polymer Miscibility, Molecular Relaxation and Phase Behavior of Dipyridamole Amorphous Solid Dispersions","volume":"110","author":"Sharma","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.xphs.2018.04.028","article-title":"Evaluation of spironolactone solid dispersions prepared by co-spray drying with Soluplus\u00ae and PVP and influence of tableting on drug release","volume":"107","author":"Odah","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.carbpol.2014.01.027","article-title":"Solid dispersion of efavirenz in PVP K-30 by conventional solvent and kneading methods","volume":"104","author":"Alves","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1021\/mp5004515","article-title":"Mechanism of Amorphous Itraconazole Stabilization in Polymer Solid Dispersions: Role of Molecular Mobility","volume":"11","author":"Bhardwaj","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1021\/acs.molpharmaceut.5b00950","article-title":"Effect of Water on Molecular Mobility and Physical Stability of Amorphous Pharmaceuticals","volume":"13","author":"Mehta","year":"2016","journal-title":"Mol. Pharm."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12215\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:22:43Z","timestamp":1760127763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":37,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241512215"],"URL":"https:\/\/doi.org\/10.3390\/ijms241512215","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,30]]}}}